Allergan Aesthetics Wins Health Canada Approval for Boey, a Fast-Acting Wrinkle Treatment

Allergan Aesthetics gains approval for Boey® (trenibotulinumtoxinE) in Canada, the foremost & only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Allergan Aesthetics, an AbbVie company, received approval from Health Canada for Boey®(trenibotulinumtoxinE), the first and only rapid-onset and short-duration botulinum neurotoxin serotype E. This is used for the temporary improvement in the appearance of moderate to severe lines between the glabellar lines in adult patients.

According to a new survey of this firm, nearly 80% of people are looking to study novel treatments to achieve the results they want, & an approximate 79% public wishes to temporarily preview the outcome of an aesthetic treatment.

About the Boey® clinical studies

The data from two randomised, multi-centre, double-blind, placebo-controlled Phase 3 clinical trials delivered an evaluation of the efficacy and safety of Boey®in adults with moderate to severe glabellar lines (M21-500 and M21-508) linked with corrugator &/or procerus muscle activity. The studies were conducted on 947 patients treated with Boey® 700 U total dose or placebo.

About Allergan Aesthetics

It is an AbbVie company, & they establish, manufacture, and market a portfolio of major aesthetics brands and products. Their portfolio primarily covers facial injectables, body contouring, plastics, skin care, and more. They aim to offer their customers innovation, education, impressive service, & a commitment to excellence, all with a personal touch.

According to Towards Healthcare, the North America bioregenerative aesthetic injectable market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.69 billion in 2026 to approximately USD 5.15 billion by 2035, representing a compound annual growth rate (CAGR) of 13.20% from 2026 to 2035. Increasing demand for minimally invasive, natural-looking treatments, ongoing advances in exosomes, polynucleotides, and collagen stimulators & a greater focus on preventive anti-ageing solutions, drive the overall market progression. Many regional clinics and MedSpas are pairing regenerative injectables with energy-based devices for rigorous, patient-customized aesthetic solutions.

Specifically, the U.S. & Canada providers are forcing the enhancement in cellular rejuvenation & AI-enabled personalization.

According to Towards Healthcare, the North America bioregenerative aesthetic injectable market is expanding, as clinics are increasingly shifting to biostimulators, which contain PLLA, Polycaprolactone (PCL), & polynucleotides. These products allow activate stimulation of fibroblast activity, enhancing natural collagen production, optimizing skin elasticity, and treating structural ageing at the cellular level. Additionally, the region has been seeking robust integration of AI-assisted digital skin analysers to look at facial tissue & trace extracellular remodeling.